• KSQ-004EX, a dual-edit eTIL investigational therapy in which both the Regnase-1 and SOCS1 genes are inactivated by CRISPR/Cas9 gene editing, is also manufactured using our ExPRESS process.
  • Using our in vivo CRISPR2TM screening approach, we identified Regnase-1 and SOCS1 as the genome’s top dual-edit combination driving best-in-biology anti-tumor potential.
  • We are currently conducting IND-enabling studies to advance KSQ-004EX into clinical development.